April/May #195 : The PrEP Report - by Benjamin Ryan

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Features

Hot & Bothered

Against All Odds

From the Editor

Sexual Healing

Feedback

Letters-April/May 2014

The POZ Q+A

Dangerous Writing

POZ Planet

Desires to Connect

Porn’s Disappearing Condom Trick!

Antigay Laws Raise HIV Concerns

Does Love Protect Against HIV?

A Military HIV Milestone

Redefining Sex at the CDC

Voices

The Last One

Care and Treatment

AIDS Caused by 'Cellular Suicide'

Condomless Sex Rises Among Gay Men

New Hep C Drug Sovaldi Approved for Coinfected Use

The PrEP Report

FDA OKs Switch to Complera

HIV Specific Poison May Complement Antiretrovirals

Research Notes

Prevention: Teens Take Risks, Still Don’t Test

Treatment: Near-Normal Life Expectancy

Cure: Dashed Hopes for Viral Remission

Concerns: Fast-Progressing HIV Strain

SeroZero by GMHC

Editor’s Note

I’m Still Here, Thank God

Research Roundup: Women Over Age 50 and HIV

Releasing Health: Reintegration and Me

What’s Really New About the HIV Epidemic and Young Black Men?

POZ Heroes

Drawing Out the Details

   
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

April / May 2014

The PrEP Report

by Benjamin Ryan

Prescribing Truvada (emtricitabine/tenofovir) to HIV-negative people as pre-exposure prophylaxis (PrEP) enjoys widespread support from infectious disease doctors—in theory, but not in practice. A large survey of physicians’ attitudes in the United States and Canada found that three-quarters of those surveyed gave the thumbs-up to this HIV prevention tool, with just 12 percent unsupportive. And yet a scant 9 percent reported ever prescribing Truvada as PrEP to their patients.

Among the reasons for doctors’ wariness were concerns about the possibility of what’s known as “risk compensation”: taking PrEP and then engaging in riskier sex. However, a new study has echoed past findings that PrEP does not actually lead to this phenomenon.

Researchers at the Gladstone Institutes, an affiliate of the University of California, San Francisco, analyzed the reported sexual behavior of those in a large study of PrEP who believed both that they were taking Truvada, as opposed to the study’s placebo, and that the drug was working. In theory, this group would be more inclined toward risk compensation, but this was not the case.

Robert M. Grant, MD, MPH, a senior investigator at Gladstone who led the study, says that the individuals he has researched over the years do not appear to want to change their sexual behavior because of PrEP.

“Many people tell me, ‘Look, I want raw sex, I’m going to get raw sex, the only question is whether I’m going to get HIV too,’” he says.

Search: PrEP, prevention, Gladstone Institutes, Truvada

Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Should the U.S. gay blood ban end?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.